101 related articles for article (PubMed ID: 25054447)
21. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses.
Chen X; Zhou H; Chen R; He J; Wang Y; Huang L; Sun L; Duan C; Luo X; Yan H
Clin Chim Acta; 2015 Feb; 440():57-63. PubMed ID: 25447698
[TBL] [Abstract][Full Text] [Related]
22. Serum human epididymis protein 4 vs. carbohydrate antigen 125 in ovarian cancer follow-up.
Ferraro S; Robbiano C; Tosca N; Panzeri A; Paganoni AM; Panteghini M
Clin Biochem; 2018 Sep; 60():84-90. PubMed ID: 30125544
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic and Prognostic Biomarkers in ovarian cancer and the potential roles of cancer stem cells - An updated review.
Muinao T; Deka Boruah HP; Pal M
Exp Cell Res; 2018 Jan; 362(1):1-10. PubMed ID: 29079264
[TBL] [Abstract][Full Text] [Related]
24. Recent Insight about HE4 Role in Ovarian Cancer Oncogenesis.
Anastasi E; Farina A; Granato T; Colaiacovo F; Pucci B; Tartaglione S; Angeloni A
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445657
[TBL] [Abstract][Full Text] [Related]
25. [HE4--a new tumor marker for ovarian cancer].
Manolov V; Marinov B; Vasilev V; Andreeva A
Akush Ginekol (Sofiia); 2011; 50 Suppl 2():11-5. PubMed ID: 22524132
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta-analysis.
Dayyani F; Uhlig S; Colson B; Simon K; Rolny V; Morgenstern D; Schlumbrecht M
Int J Gynecol Cancer; 2016 Nov; 26(9):1586-1593. PubMed ID: 27540691
[TBL] [Abstract][Full Text] [Related]
27. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
[TBL] [Abstract][Full Text] [Related]
28. Alternative tumor markers in the diagnosis of ovarian cancer.
Karakaya BK; Başer E; Bildacı B; Cömert EÇ; Bayraktar N; Dursun P; Kuşçu E; Ayhan A
Ginekol Pol; 2016; 87(8):565-769. PubMed ID: 27629130
[TBL] [Abstract][Full Text] [Related]
29. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
[TBL] [Abstract][Full Text] [Related]
30. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
[TBL] [Abstract][Full Text] [Related]
31. Are serum HE4 or ROMA scores useful to experienced examiners for improving characterization of adnexal masses after transvaginal ultrasonography?
Kaijser J; Van Gorp T; Smet ME; Van Holsbeke C; Sayasneh A; Epstein E; Bourne T; Vergote I; Van Calster B; Timmerman D
Ultrasound Obstet Gynecol; 2014 Jan; 43(1):89-97. PubMed ID: 23828371
[TBL] [Abstract][Full Text] [Related]
32. Biparametric Magnetic Resonance Imaging as an Adjunct to CA125 and HE4 to Improve Characterization of Large Ovarian Masses.
Manganaro L; Anastasi E; Porpora MG; Vinci V; Saldari M; Bernardo S; Ballesio L; Sollazzo P; Pecorella I; Recchia N; Stracci F; Panici PB; Angeloni A; Catalano C; Scialpi M
Anticancer Res; 2015 Nov; 35(11):6341-51. PubMed ID: 26504074
[TBL] [Abstract][Full Text] [Related]
33. Human epididymis protein 4 (HE4) in benign and malignant diseases.
Hertlein L; Stieber P; Kirschenhofer A; Krocker K; Nagel D; Lenhard M; Burges A
Clin Chem Lab Med; 2012 Dec; 50(12):2181-8. PubMed ID: 23093276
[TBL] [Abstract][Full Text] [Related]
34. Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women.
Holcomb K; Vucetic Z; Miller MC; Knapp RC
Am J Obstet Gynecol; 2011 Oct; 205(4):358.e1-6. PubMed ID: 21722869
[TBL] [Abstract][Full Text] [Related]
35. Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease.
Zheng H; Gao Y
Int J Gynecol Cancer; 2012 Jul; 22(6):1000-5. PubMed ID: 22426406
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic performance and establishment of reference limits of HE4 in Korean healthy women.
Yu S; Lee JK; Kim JH; Park H; Lee MY; Ryu S; Kwon MJ; Woo HY
Gynecol Oncol; 2016 Oct; 143(1):128-134. PubMed ID: 27426308
[TBL] [Abstract][Full Text] [Related]
37. Role of BRCA Mutation and HE4 in Predicting Chemotherapy Response in Ovarian Cancer: A Retrospective Pilot Study.
Plotti F; Terranova C; Guzzo F; De Cicco Nardone C; Luvero D; Bartolone M; Dionisi C; Benvenuto D; Fabris S; Ciccozzi M; Di Donato V; Panici PB; Angioli R
Biomedicines; 2021 Jan; 9(1):. PubMed ID: 33435590
[TBL] [Abstract][Full Text] [Related]
38. HE4 and eIF3a Expression Correlates with Surgical Outcome and Overall Survival in Ovarian Cancer Patients with Secondary Cytoreduction.
Luo CH; Zhao M; Chen XY; Shahabi S; Qiang W; Zeng L; Wang J; Zhou HH
J Cancer; 2018; 9(14):2472-2479. PubMed ID: 30026845
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of He4 Use in the Diagnosis of Ovarian Cancer: First and Second Recurrence, and an Analysis of HE4 Concentration during Second- and Third-Line Chemotherapy.
Chudecka-Głaz A; Strojna A; Michalczyk K; Wieder-Huszla S; Safranow K; Skwirczyńska E; Jurczak A
Diagnostics (Basel); 2023 Jan; 13(3):. PubMed ID: 36766556
[TBL] [Abstract][Full Text] [Related]
40. Tumor Markers and Their Diagnostic Significance in Ovarian Cancer.
Matsas A; Stefanoudakis D; Troupis T; Kontzoglou K; Eleftheriades M; Christopoulos P; Panoskaltsis T; Stamoula E; Iliopoulos DC
Life (Basel); 2023 Aug; 13(8):. PubMed ID: 37629546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
